08:39 AM EDT, 06/03/2025 (MT Newswires) -- Chemomab Therapeutics ( CMMB ) said Tuesday that China and Russia awarded new patents covering the use of its lead product nebokitug to treat liver diseases including primary sclerosing cholangitis.

The patent from China protects the usage of nebokitug in hepatic diseases and provides coverage through 2038, while the patent from Russia protects the usage of different nebokitug formulations and doses and provides coverage through 2041, the company said.

Chemomab continues to advance potential collaborations to support a nebokitug phase 3 registrational trial in primary sclerosing cholangitis, Co-Founder and Chief Executive Officer Adi Mor said.